AML 2021: Strategies for Attack Before Diagnosis and After Remission – Module 2

Access Activity

Overview / Abstract:

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Program Overview

This activity provides an overview of important genetic mutations in acute myeloid leukemia and recent therapeutic advances.

Learning Objective

Upon completion of this activity, participants should be better able to:

Identify the impact of minimal residual disease (MRD) analysis and pre-leukemic clones on the treatment of acute leukemia


Mar 02, 2023


Physician CME



Credits / Hours

1.0 AMA PRA Category 1 Credit(s)™



Presenters / Authors / Faculty


Gail J. Roboz, MD
Professor, Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
Division of Hematology and Oncology
New York-Presbyterian Hospital
New York, NY

Sponsors / Supporters / Grant Providers

The Leukemia & Lymphoma Society

Keywords / Search Terms

Relias LLC Relias LLC., FreeCME., Leukemia, Lymphoma Free CE CME

Access Activity

CORE Higher Education Group,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps.CORE Higher Education Group,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the Terms of Service. Site Map